{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:13:06Z","timestamp":1766268786501},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urology"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.urology.2006.10.007","type":"journal-article","created":{"date-parts":[[2007,2,22]],"date-time":"2007-02-22T14:28:35Z","timestamp":1172154515000},"page":"347-351","source":"Crossref","is-referenced-by-count":10,"title":["Phase II Trial of Gemcitabine, Prednisone, and Zoledronic Acid in Pretreated Patients with Hormone Refractory Prostate Cancer"],"prefix":"10.1016","volume":"69","author":[{"given":"Giuseppe","family":"Di Lorenzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Autorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Napodano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniello","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Benincasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimino","family":"D\u2019Armiento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabino","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2006.10.007_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer statistics","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2006.10.007_bib2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0090-4295(99)80182-4","article-title":"Hormone refractory (D3) prostate cancer: refining the concept","volume":"46","author":"Scher","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.urology.2006.10.007_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0090-4295(99)00447-1","article-title":"Overview: hormone refractory prostate cancer","volume":"54","author":"Crawford","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.urology.2006.10.007_bib4","first-page":"10","article-title":"Hormone refractory prostate cancer (HRPC): present and future approaches of therapy","volume":"19","author":"Di Lorenzo","year":"2006","journal-title":"Int J Immunol Pharm"},{"key":"10.1016\/j.urology.2006.10.007_bib5","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2006.10.007_bib6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrilak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2006.10.007_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3816\/CGC.2004.n.022","article-title":"Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?","volume":"3","author":"Rosenberg","year":"2004","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.urology.2006.10.007_bib8","first-page":"25","article-title":"Phase I studies with the novel nucleoside analog, gemcitabine","volume":"23","author":"Abbruzzese","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1016\/j.urology.2006.10.007_bib9","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomised study","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2006.10.007_bib10","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2006.10.007_bib11","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.urology.2006.10.007_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y","article-title":"The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group","volume":"50","author":"Tong","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2006.10.007_bib13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Non parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.urology.2006.10.007_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1008332724977","article-title":"for the Swiss Group for Clinical Cancer Research (SAKK): Response and palliation in a phase II trial of gemcitabine in hormone refractory metastatic carcinoma","volume":"11","author":"Morant","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urology.2006.10.007_bib15","first-page":"1700","article-title":"Short-term efficacy of combined chemotherapy of gemcitabine and cisplatin on advanced hormone refractory prostate cancer","volume":"23","author":"Qin","year":"2004","journal-title":"Ai Zheng"},{"key":"10.1016\/j.urology.2006.10.007_bib16","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1464-410X.2005.05799.x","article-title":"Satraplatin in the treatment of hormone refractory prostate cancer","volume":"96","author":"Sternberg","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2006.10.007_bib17","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.urology.2004.10.033","article-title":"Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study","volume":"65","author":"Urakami","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.urology.2006.10.007_bib18","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2004.08.022","article-title":"Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer","volume":"46","author":"Di Lorenzo","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2006.10.007_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1158\/1078-0432.284.11.1","article-title":"A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer","volume":"11","author":"Oh","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"suppl 6A","key":"10.1016\/j.urology.2006.10.007_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.urology.2005.04.020","article-title":"Future directions in the treatment of androgen-independent prostate cancer","volume":"65","author":"Petrylak","year":"2005","journal-title":"Urology"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429506023442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429506023442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T19:09:16Z","timestamp":1683745756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429506023442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0090429506023442"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2006.10.007","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}